
|Videos|August 21, 2017
Dr. Stephenson on the Development of Biomarkers for Prostate Cancer
Author(s)Andrew J. Stephenson, MD
Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
Advertisement
Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.
It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































